Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.

ABSTRACT:

Background

Osteosarcoma (OS) is the most common bone malignancy in the paediatric population, principally affecting adolescents and young adults. Minimal advancements in patient prognosis have been made over the past two decades because of the poor understanding of disease biology. Runx2, a critical transcription factor in bone development, is frequently amplified and overexpressed in OS. However, the molecular and biological consequences of Runx2 overexpression remain unclear.

Methods

si/shRNA and overexpression technology to alter Runx2 levels in OS cells. In vitro assessment of doxorubicin (doxo)-induced apoptosis and in vivo chemosensitivity studies. Small-molecule inhibitor of c-Myc transcriptional activity was used to assess its role.

Results

Loss of Runx2 sensi

SUBMITTER: Roos A 

PROVIDER: S-EPMC4815801 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature